Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vofopitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vofopitant SCHEMBL310338 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL30522777 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8901341 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL30522778 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8431760 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL7062769 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8316732 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL310793 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL5153521 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL29711142 | 0.99 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | claimed |
| EP-1080080-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-07 | — | — | EP | claimed |
| EP-1080080-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999064000-A9 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999064000-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| CN-118252832-A | Use of Vofopitant for the treatment of scleroderma | 上海数因信科智能科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20220218663-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-07-14 | — | — | US | disclosed |
| US-20210100773-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2021-04-08 | — | — | US | disclosed |
| US-10729677-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-I | EUSTRALIS PHARMACEUTICAL LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2020-08-04 | — | — | US | disclosed |
| EP-3016642-B1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LTD TRADING AS PRESSURA NEURO (AU) | 2019-03-13 | — | — | EP | disclosed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-6140324-A | ADMINISTERING TACHYKININ ANTAGONIST AND MUSCARINIC ANTAGONIST AND/OR ANTIHISTAMINE, SUCH THAT THEY GIVE EFFECTIVE RELIEF FROM MOTION SICKNESS | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | disclosed |
| WO-1999064000-A9 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | disclosed |
| EP-0977573-A1 | USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999064000-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5981526-A | SYNERGISTIC TREATMENT OR PREVENTION OF MIGRAINE | MERCK SHARP & DOHME LTD. (GB) | 1999-11-09 | — | — | US | disclosed |
| WO-1998047514-A1 | USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.